Evidence-based coverage of GLP-1 medications, telehealth, FDA updates, and clinical developments. https://goglp1.com/blog/ en-us Thu, 28 May 2026 19:52:51 GMT editorial@goglp1.com (GoGLP1 Editorial Team) webmaster@goglp1.com (GoGLP1) https://goglp1.com/blog/fda-generic-glp1-approval-2026/ https://goglp1.com/blog/fda-generic-glp1-approval-2026/ Everything you need to know about the FDA's progress on generic GLP-1 approvals in 2026, including semaglutide, tirzepatide, pricing, and what it means for you. Wed, 20 May 2026 00:00:00 GMT GoGLP1 Editorial Team FDA generic GLP-1 semaglutide tirzepatide pricing https://goglp1.com/blog/semaglutide-compounding-rules-june-2026/ https://goglp1.com/blog/semaglutide-compounding-rules-june-2026/ The FDA has announced new compounding regulations for GLP-1 medications. Here is what patients and telehealth providers need to know about sourcing compounded semaglutide safely. Fri, 08 May 2026 00:00:00 GMT GoGLP1 Editorial Team compounding FDA semaglutide regulation https://goglp1.com/blog/retatrutide-phase3-results-2026/ https://goglp1.com/blog/retatrutide-phase3-results-2026/ Eli Lilly has released Phase 3 clinical trial data for retatrutide, showing unprecedented weight loss results. Here is what the data means for patients and the GLP-1 market. Tue, 05 May 2026 00:00:00 GMT GoGLP1 Editorial Team retatrutide clinical-trials weight-loss Eli-Lilly https://goglp1.com/blog/glp1-muscle-loss-protein-protocol/ https://goglp1.com/blog/glp1-muscle-loss-protein-protocol/ A new clinical study demonstrates that a structured protein intake protocol combined with resistance exercise can significantly reduce muscle loss during GLP-1 therapy. Tue, 28 Apr 2026 00:00:00 GMT GoGLP1 Editorial Team nutrition muscle-loss protein side-effects